SMO and skin basal cell carcinoma: Although both FDA-approved SMO antagonists were initially successful in the treatment of BCC or MB, they rapidly caused drug resistance due to acquired mutations within the SMO-transmembrane domain, which prevent the binding of the drugs [15,16].